Veru (NASDAQ:VERU) posted its quarterly earnings data on Thursday. The company reported ($0.04) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.04), Fidelity Earnings reports. Veru had a negative net margin of 91.61% and a negative return on equity of 64.91%. The company had revenue of $9.73 million during the quarter, compared to the consensus estimate of $8.11 million. Veru updated its FY 2019 guidance to EPS.
Shares of VERU stock traded down $0.16 on Friday, reaching $1.96. The stock had a trading volume of 376,987 shares, compared to its average volume of 181,255. The company has a quick ratio of 0.99, a current ratio of 1.25 and a debt-to-equity ratio of 0.08. The stock’s 50-day moving average price is $2.22. The stock has a market capitalization of $134.37 million, a price-to-earnings ratio of -5.03 and a beta of 0.37. Veru has a 12 month low of $1.18 and a 12 month high of $2.49.
In other news, insider Mitchell Shuster Steiner sold 20,000 shares of the company’s stock in a transaction dated Wednesday, June 5th. The shares were sold at an average price of $1.98, for a total value of $39,600.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Over the last ninety days, insiders sold 70,000 shares of company stock worth $152,400. 29.50% of the stock is owned by insiders.
Veru Inc operates as an oncology and urology biopharmaceutical company. The company operates through two segments, Commercial, and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation.
Featured Story: What is Put Option Volume?
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.